Abstract
Major Depressive Disorder (MDD) is a leading cause of global disability. While Electroconvulsive Therapy (ECT) is highly effective for treatment-resistant cases, its clinical utility is often limited by cognitive side effects. This paper presents the protocol for a large-scale, multicenter, double-blind, randomized, non-inferiority trial (ClinicalTrials.gov: NCT06409325) designed to compare Magnetic Seizure Therapy (MST) with ECT in China. The primary objective is to determine if MST can match the antidepressant efficacy of ECT while significantly reducing the "cognitive tax" associated with seizure therapy.
Introduction: Addressing the Cognitive Cost of Seizure Therapy
Electroconvulsive Therapy (ECT) remains the gold standard for rapid relief from severe depression. However, the electrical currents used in ECT are diffused by the skull, often affecting deep-brain structures like the hippocampus, which leads to short-term amnesia and cognitive impairment.
Magnetic Seizure Therapy (MST) has emerged as a promising alternative. Unlike ECT, which uses electrical currents that diffuse through the scalp and skull, MST uses high-intensity magnetic fields to induce seizures. Because magnetic fields pass through the skull without resistance, MST can be more "focal," targeting the superficial cortex rather than deep-brain structures. This theoretical advantage suggests that MST could provide the therapeutic benefits of a seizure without the widespread cognitive disruption seen in ECT. This protocol describes the first large-scale trial in China aimed at providing definitive evidence for this transition.
Methodology and Study Design
The study is a multicenter trial involving seven clinical centers in China, targeting a total of 210 participants diagnosed with MDD.
Trial Structure
Participants are randomized 1:1 into either the MST or ECT treatment groups. Both interventions consist of 12 sessions administered over a four-week period. To maintain the double-blind nature of the study, a "sham sound" protocol is employed: recorded MST sounds are played during ECT sessions to ensure that neither patients nor evaluators can distinguish the treatments based on auditory cues.
Assessment and Outcomes
The primary efficacy outcome is the change in the 24-item Hamilton Depression Rating Scale (HDRS-24) from baseline to the 12-week follow-up. Cognitive safety is monitored using the Hopkins Verbal Learning Test-Revised (HVLT-R) to assess verbal memory.
Beyond clinical scores, the trial incorporates neurophysiological biomarkers to move toward precision psychiatry:
- Resting-state EEG (rsEEG): To identify brain wave patterns associated with treatment response.
- Heart Rate Variability (HRV): 10-minute resting ECG recordings are used to analyze 14 different HRV indices as potential predictors of efficacy.
Theoretical Framework: Focality vs. Diffusion
The core innovation of MST lies in the physics of the skull. In ECT, the electrical current is highly resisted by bone, causing it to spread and impact the hippocampus. In contrast, MST’s magnetic field is unimpeded, allowing for "surgical" seizure induction in the prefrontal cortex. The trial's non-inferiority design aims to prove that MST is "not worse" than ECT in treating depression while being significantly safer for cognitive function.
Expected Results and Discussion
As this is a protocol paper, quantitative results are pending. The trial commenced in late 2024 and is expected to conclude in 2027. Researchers anticipate that MST will demonstrate non-inferior antidepressant effects compared to ECT, with MST patients showing superior performance in verbal memory and psychomotor speed.
Limitations and Future Directions
Several limitations are noted in the study design:
- Dosing Precision: The use of age-based dosing for ECT, while common in China, may be less precise than individual seizure threshold titration.
- Memory Domains: The current battery lacks a dedicated test for autobiographical memory, which is particularly sensitive to ECT.
- Follow-up Duration: The 12-week window may not fully capture long-term relapse rates or the complete trajectory of cognitive recovery.
Future work will involve using the neurophysiological data collected here to develop machine learning models that can predict treatment response before the first session begins, tailoring seizure therapy to the individual patient.
Summary updated